An estimated 64 million Americans have elevated levels of lipoprotein(a), or Lp(a), a type of cholesterol that can increase ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Millions of Americans are born predisposed to high levels of a cholesterol called lipoprotein(a). Doctors are finally figuring out how to treat it.

Lowering your “bad” cholesterol might be doing more than just protecting your heart, it could also be safeguarding your brain ...

A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...